> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Grants Genea Biocells Orphan Drug Designation
- URL: https://www.fdaweb.com/fda-grants-genea-biocells-orphan-drug-designation/
- Published: 2018-05-31T12:00:00.000Z
- Updated: 2026-09-15T00:09:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141578

FDA has granted Genea Biocells an orphan drug designation for GBC0905 and its use in treating facioscapulohumeral muscular dystrophy (FSHD). The company says the small molecule agent works by suppressing DUX4 function, the molecular cause of the disease. It says FSHD is one of the most common muscular dystrophies and results in progressive muscle weakness. Genea Biocells says the designation validates its “skeletal muscle technology which is a highly useful platform for modeling any number of other myogenic indications as we expand our pipeline.” Currently, the company is planning to advance GBC0905 to clinical trials, complete preclinical work on its Spinal Muscular Atrophy (SMA) program, and expand the pipeline to other orphan muscle diseases.